Jayastu Senapati, MBBS
Department of Leukemia, Division of Cancer Medicine
About Dr. Jayastu Senapati
Dr. Senapati is an Assistant Professor in the Dept of Leukemia at the University of Texas MD Anderson Cancer Center, Houston Texas. He graduated from the Christian Medical College at Vellore in India followed by further residency in Internal Medicine in the same institution followed by Clinical Hematology fellowship at AIIMS, New Delhi. He subsequently did a leukemia fellowship at MD Anderson Cancer Center and joined the department as faculty. Dr. Senapati treats patients with acute and chronic leukemias and focuses on management of critical acute leukemia patients. He believes in patient centric leukemia care, that is driven by the latest research and evidence-based medicine. His research focus is primarily on acute myeloid leukemia and acute lymphoblastic leukemia, and he has been involved in several clinical trials and research projects. He has important publications on leukemia therapy and management in high-impact journals like Lancet Haematology, Journal of Clinical Oncology, Blood, Leukemia, Clinical Cancer Research, Blood Cancer Journal, Cancer, Haematologica amongst others. He has presented several important data in national and international conferences like American Society of Hematology, American Society of Clinical Oncology and European Hematology Association annual meetings. During his medical training, residency, and fellowships he has received several awards including a coveted National Scholarship by the Govt. of India, S.C. Devadutta Award in Biochemistry, Paul Harrison Award in Neurology, J.C.M. Shastry Award in nephrology, P.H. Chandrashekhar Gold Medal in Infections Diseases, Mammen Chandy Gold Medal in Hematology, Post Graduate Gold Medal in Rheumatology, M.S Seshadri Award in Endocrinology, amongst others. During his leukemia fellowship at MD Anderson Cancer Center, he received the Best Leukemia Research Fellow of the Year Award and Best Leukemia Clinical Fellow of the Year Award in successive years. Dr. Senapati works with a team of well-trained and empathetic nurses and mid-level providers whose primary focus is to offer the best treatment approach for their patients and holistic care.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Affiliate Faculty of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia
MPAL- Mixed Phenotypic Acute Leukemia
Clinical Interests
AML- Acute Myeloid Leukemia
ALL- Acute Lymphoblastic Leukemia
MPAL- Mixed Phenotypic Acute Leukemia
CML- Chronic Myeloid Leukemia
CLL- Chronic Lymphocytic Leukemia
AA- Aplastic Anemia
Education & Training
Degree-Granting Education
| 2012 | Christian Medical College and Hospital, Vellore, Tamil Nadu, IN, Medicine, MBBS |
Postgraduate Training
| 2021-2023 | Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2021 | Clinical Fellowship, D. M. Clinical Hematology, All India Institute of Medical Sciences, New Delhi |
| 2015-2018 | Clinical Residency, Internal Medicine, Christian Medical College, Vellore |
Licenses & Certifications
| 2023 | Texas Medical Board |
| 2023 | Faculty Temporary License |
Experience & Service
Faculty Academic Appointments
Fellow, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Senior Resident, Clinical Haematology, All India Institute of Medical Sciences, New Delhi, 2018 - 2021
Resident, Internal Medicine, Christian Medical College, Vellore, 2018 - 2021
Clinical Assistant, Medical Intensive Care Unit, Christian Medical College, Vellore, 2014 - 2015
Clinical Assistant, Clinical Hematology, Christian Medical College, Vellore, 2013 - 2014
Internship, Christian Medical College, Vellore, 2012 - 2013
Administrative Appointments/Responsibilities
Advisor, Resident Doctor's Association, All India Institute of Medical Sciences, New Delhi, 2021 - 2021
Resident's Batch Representative, Internal Medicine, Christian Medical College, Vellore, 2018 - 2021
Editorial Activities
Editor, BMC Cancer, 2023
Honors & Awards
| 2023 | ASH Abstract Achievement Award, American Society of Hematology |
| 2023 | Alumni Recognition and Gratitude Award, St. Xavier's School, Durgapur, West Bengal, India |
| 2022 | ASH Abstract Achievement Award, American Society of Hematology |
| 2022 | Leukemia Clinical Fellow of the Year, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston |
| 2022 | Leukemia Research Fellow of the Year, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston |
| 2022 | EHA Congress Travel Award, European Hematology Association |
| 2022 - 2023 | ASCO Conquer Cancer Merit Award, American Society of Clinical Oncology |
| 2021 | COVID-19 Warrior Award for Exceptional Care to patients during the COVID-19 pandemic, Resident Doctor's Association, All India Institute of Medical Sciences, New Delhi, India |
| 2020 | First Place in Malignant Hematology Quiz at RGCON, Rajiv Gandhi Cancer Institute and Research Centre |
| 2020 | Second Place in National Round of Indian Myeloma Congress Quiz, Indian Myeloma Academic Groupe |
| 2017 | First Place in National Hematology Quiz, Indian Society of Hematology and Transfusion Medicine |
| 2017 | Post Graduate Gold Medal in Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Christian Medical College and Hospital, Vellore, India |
| 2016 | Best Oral Paper in Malignant Clinical Hematology, Hematocon 2016, Indian Society of Hematology and Transfusion Medicine |
| 2016 | Post Graduate Gold Medal in Hematology, Department of Hematology, Christian Medical College and Hospital, Vellore, India |
| 2016 | M. S. Seshadri Prize in Endocrinology for postgraduate residents in MD Medicine/Pediatrics, Department of Endocrinology, Christian Medical College and Hospital, Vellore, India |
| 2016 | First Place in State and Zonal Round of Indian Rheumatology Association Quiz, Indian Rheumatology Association |
| 2015 | First Place in National Hematology Quiz, Indian Society of Hematology and Transfusion Medicine |
| 2015 | P.H. Chandrasekhar Post Graduate Gold Medal in Infectious Disease, Department of Infectious Disease, Christian Medical College and Hospital, Vellore |
| 2015 | First Place in Clinical Infectious Disease Society of India National Quiz, Clinical Infectious Disease Society of India |
| 2011 | National Refresher Course in Pediatrics Quiz, Sri Ramachandra Medical College and Hospital, Chennai |
| 2011 | Indian Academy of Pediatrics Quiz for Undergraduate Medical Students, Indian Academy of Pediatrics |
| 2011 | Captain JaiSingh Jadhav Prize in Pediatrics, Department of Child Health, Christian Medical College and Hospital, Vellore, India |
| 2011 | J.C.M. Shastry, Department of Nephrology, Christian Medical College and Hospital, Vellore, India |
| 2010 | S. C. Devadutta Prize in Biochemistry, Department of Biochemistry, Christian Medical College and Hospital, Vellore, India |
| 2010 | Undergraduate Endocrinology Quiz, Department of Endocrinology, Christian Medical College and Hospital, Vellore, India |
| 2010 | Fujio Cup Quiz on Stem Cells and Regenerative Medicine, Nichi-in Center for Regenerative Medicine, India |
| 2009 | Paul Harrison Award in Neurology, Department of Neurology, Christian Medical College and Hospital, Vellore, India |
| 2005 | National talent Search Examination Scholar, National Council of Education Research and Training, Govt. of India |
Professional Memberships
Selected Presentations & Talks
Formal Peers
- 2024. Optimal use of Azacitidine and Ventoclax in AML. Invited, IN.
Selected Publications
Peer-Reviewed Articles
- Azevedo RS, Jabbour E, Jain N, Haddad FG, Kebriaei P, Khouri I, Shpall EJ, Champlin R, Karrar O, Maroun M, Senapati J, Kugler E, Garris RS, Ravandi F, Kantarjian H, Short NJ. Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage. Leukemia 40(9):2008-2017, 2026. e-Pub 2026. PMID: 42463941.
- Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Zucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carre M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol 44(25):2422-2434, 2026. e-Pub 2026. PMID: 42391582.
- Arora S, Senapati J, Chu V, Pemmaraju N, Bose P, Jabbour E, Kadia T, Ning J, Saenz D, Zhou L, Halim H, Alvarado Y, Ohanian M, DiNardo C, Takahashi K, Jain N, Ravandi F, Kantarjian H, Garcia-Manero G, Masarova L, Daver N. Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis. Haematologica, 2026. e-Pub 2026. PMID: 42657929.
- Kugler E, Ravandi F, Bazinet A, Dinardo CD, Daver N, Yilmaz M, Short NJ, Jen WY, Senapati J, Maiti A, Borthakur G, Garcia-Manero G, Kantarjian HM, Kadia TM. Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remission. Haematologica, 2026. e-Pub 2026. PMID: 42489069.
- Htut TW, Kekedjian J, Short N, Bazinet A, Alvarado Y, Bataller A, Issa G, Borthakur G, Maiti A, Yilmaz M, Jain N, Masarova L, Chien K, Senapati J, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Garcia-Manero G, Ravandi F. Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia. Haematologica, 2026. e-Pub 2026. PMID: 42389833.
- Senapati, J, Kantarjian, HM, Ayoub, E, Quesada, AE, Loghavi, S, Sasaki, K, Kadia, TM, Daver, N, DiNardo, C, Jain, A, McCabe, M, Haddad, FG, Brandt, M, Tang, G, Alvarado, Y, Farish, K, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Andreeff, M, Borthakur, G. Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial. Blood Cancer Discovery 7(4):572-585, 2026. e-Pub 2026. PMID: 41979452.
- Senapati, J, Daver, N. Response to Comment on. Haematologica 111(7):2550-2551, 2026. e-Pub 2026. PMID: 41063701.
- Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG. Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. J Hematol Oncol 19(1), 2026. e-Pub 2026. PMID: 42304430.
- Fiskus, WC, Mill, CP, Issa, GC, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Hou, H, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, DE, Senapati, J, Loghavi, S, Flores, L, Su, X, DiNardo, C, Bhalla, K. Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood 147(23):2809-2820, 2026. e-Pub 2026. PMID: 41734382.
- Marvin-Peek, J, DiNardo, C, Loghavi, S, Ravandi-Kashani, F, Borthakur, G, Daver, N, Kadia, TM, Jabbour, EJ, Dunbar, A, Tang, G, Short, NJ, Haddad, FG, Abbas, HA, Kugler, E, Maiti, A, Issa, GC, Takahashi, K, Bhalla, K, Pemmaraju, N, Alvarado, Y, Shpall, E, Popat, UR, Ramdial, JL, Champlin, RE, Kantarjian, HM, Garcia-Manero, G, Senapati, J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer 132(10), 2026. e-Pub 2026. PMID: 42089434.
- Senapati, J, Croden, J, Garcia-Manero, G, Takahashi, K, Daver, N, Kadia, TM, Borthakur, G, Short, NJ, Jabbour, EJ, Haddad, FG, Marvin-Peek, J, Abbas, HA, Bose, P, Tang, G, Loghavi, S, Shpall, E, Ramdial, JL, Popat, UR, Champlin, RE, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. HemaSphere 10(2), 2026. e-Pub 2026. PMID: 41694734.
- Short, NJ, Kantarjian, HM, Jain, N, Kadia, TM, Senapati, J, Haddad, FG, Maroun, MM, Sasaki, K, Xiao, L, Huang, X, Karrar, OS, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Jabbour, EJ. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia. Blood Advances 10(1):25-28, 2026. e-Pub 2026. PMID: 40763277.
- Braish, J, Kantarjian, HM, Short, NJ, Tang, G, Daver, N, Kadia, TM, Senapati, J, Jen, WY, Takahashi, K, Garris, R, Garcia-Manero, G, Ravandi-Kashani, F, Jabbour, EJ, Jain, N. Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements. Clinical Lymphoma, Myeloma and Leukemia 26(1):e110-e113.e1, 2026. e-Pub 2026. PMID: 41125471.
- Franklin, S, Sahasrabhojane, P, Hayase, T, Hayase, E, Chang, C, Senapati, J, Desikan, SP, Kadia, TM, Lorenzi, PL, Jenq, RR, Shelburne, S, Galloway-Pena, J. Short-chain fatty acid-producing microbes differentiate differentiate differentiate differentiate non-infectious and infectious neutropenic fever in leukemia. mSystems 11(4):1-18, 2026. e-Pub 2026. PMID: 41914747.
- Short, NJ, Kantarjian, HM, Furudate, K, Jain, N, Ravandi-Kashani, F, Karrar, OS, Loghavi, S, Nasr, L, Haddad, FG, Senapati, J, Garris, R, Takahashi, K, Jabbour, EJ. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40369607.
- Senapati, J, Konopleva, M, Issa, GC, Jabbour, EJ, Kadia, TM, DiNardo, C, Borthakur, G, Pemmaraju, N, Short, NJ, Yilmaz, M, Deshmukh, I, Alvarez, J, Loghavi, S, Tang, G, Abbas, HA, Andreeff, M, Bhalla, K, Midde, NM, Said, N, Noyalis, A, Mires, DE, Ning, J, Xiao, L, Ravandi-Kashani, F, Garcia-Manero, G, Kantarjian, HM, Daver, N. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 41310838.
- Azevedo, RS, Jen, WY, Hammond, DE, Haddad, FG, Geppner, A, Issa, GC, Sasaki, K, Senapati, J, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell/myeloid mixed phenotype acute leukemia. Haematologica 110(12):3129-3132, 2025. e-Pub 2025. PMID: 40568715.
- Goulart, H, Ravandi-Kashani, F, Short, NJ, Jain, N, Daver, N, Kadia, TM, DiNardo, C, Borthakur, G, Takahashi, K, Pemmaraju, N, Haddad, FG, Montalban Bravo, G, Alvarado, Y, Issa, GC, Bataller Torralba, A, Pierce, S, Loghavi, S, Tang, G, Wang, S, Thakral, B, Shpall, E, Champlin, RE, Khouri, IF, Kebriaei, P, Garcia-Manero, G, Sasaki, K, Jabbour, EJ, Senapati, J. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41370732.
- Karrar O, Kantarjian H, Haddad FG, Azevedo RS, Issa G, Ravandi F, Sasaki K, Senapati J, Abbas H, Dellasala S, Jabbour E, Short NJ. Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 66(12):2269-2276, 2025. e-Pub 2025. PMID: 40782369.
- Habib, D, Jabbour, EJ, Bataller Torralba, A, Sasaki, K, Tang, G, Loghavi, S, Li, S, Senapati, J, Short, NJ, Jain, N, Kantarjian, HM, Haddad, FG. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clinical Lymphoma, Myeloma and Leukemia 25(9):672-675, 2025. e-Pub 2025. PMID: 40222876.
- Arora, S, Jen, WY, Yilmaz, M, Deshmukh, I, Senapati, J, Loghavi, S, Issa, GC, Short, NJ, Kadia, TM, DiNardo, C, Borthakur, G, Jabbour, J, Pemmaraju, N, Andreeff, M, Takahashi, K, Bhalla, K, Popat, UR, Shpall, E, Oran, B, Abbas, HA, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations. Cancer 131(16), 2025. e-Pub 2025. PMID: 40782343.
- Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
- Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Daver, N, Senapati, J, Kantarjian, HM, Wang, B, Reville, PK, Loghavi, S, Yilmaz, M, DiNardo, C, Kadia, TM, Yassouf, MY, Maiti, A, Arora, S, Montalban Bravo, G, Tang, G, Borthakur, G, Sasaki, K, Pemmaraju, N, Alvarez, J, Nogueras Gonzalez, G, Ning, J, Issa, GC, Konopleva, M, Andreeff, M, Ravandi-Kashani, F, Garcia-Manero, G, Abbas, HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia. Clinical Cancer Research 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
- Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
- Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
- Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Gangat, N, Elbeih, A, Ghosoun, N, McCullough, K, Aperna, F, Johnson, IM, Abdelmagid, M, Al-Kali, A, Alkhateeb, HB, Begna, K, Elliott, MA, Mangaonkar, AA, Matin, A, Saliba, AN, Hefazi Torghabeh, M, Litzow, M, Hogan, WJ, Shah, MV, Patnaik, MM, Pardanani, A, Badar, T, Murthy, H, Foran, J, Palmer, J, Sproat, L, Khera, N, Arana Yi, C, Yates, S, Sneider, A, Dworkin, E, Patel, A, Bazinet, A, Senapati, J, Bataller Torralba, A, DiNardo, C, Kadia, TM, Tefferi, A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. American journal of hematology 100(2):260-271, 2025. e-Pub 2025. PMID: 39671248.
- Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, Tang G, Jabbour E, DiNardo CD, Daver N, Montalban-Bravo G, Shah V, Alousi A, Shpall E, Popat U, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation. Am J Hematol 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
- Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol, 2025. e-Pub 2025. PMID: 39757533.
- Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
- Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, N, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
- Haddad FG, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, Jabbour E, Kantarjian H. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clin Lymphoma Myeloma Leuk 25(4):254-257, 2024. e-Pub 2024. PMID: 39592322.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
- Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 24(10):732-735, 2024. e-Pub 2024. PMID: 38945779.
- Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
- Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42(17):2071-2079, 2024. e-Pub 2024. PMID: 38552193.
- Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5. e-Pub 2024. PMID: 38856690.
- Short, NJ, Jabbour, EJ, Jain, N, Senapati, J, Nasr, L, Haddad, FG, Li, Z, Hsiao, YC, Yang, JJ, Pemmaraju, N, Ohanian, M, Wierda, WG, Montalban Bravo, G, Borthakur, G, Han, L, Xiao, L, Huang, X, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Advances 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
- Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
- Senapati J, Panda T, Rajendra A, Aggarwal M. Understanding the barriers to AML care in India. Lancet Haematol 10(9):e710-e711, 2023. e-Pub 2023. PMID: 37652600.
- Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
- Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
- Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
- Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
- Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2023. PMID: 36565294.
- Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 141(6):567-578, 2023. e-Pub 2023. PMID: 36399715.
- Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
- Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):2701-2705, 2022. e-Pub 2022. PMID: 35787095.
- Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
- Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
- Senapati J, Devasia AJ, Korula A, Fouzia NA, Kulkarni U, Lakshmi KM, Lionel S, Abraham A, Srivastava A, Mathews V, George B. Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience. Indian J Hematol Blood Transfus 38(2):290-298, 2022. e-Pub 2022. PMID: 35496963.
- Kumar P, Aggarwal M, Dhawan R, Dass J, Kumar G, Sharma V, Mirza S, Senapati J, Ganju N, Vaid T, Vijayran M, Panda T, Pragna GS, Krishna SS, Khandelwal A, Verghese R, Tyagi S, Seth T, Mahapatra M. Tele-Medicine Services in Hematological Practice During Covid Pandemic: Its Feasibility and Difficulties. Indian J Hematol Blood Transfus 37(4):528-533, 2021. e-Pub 2021. PMID: 33250594.
- Senapati J, Dhawan R, Aggarwal M, Kumar P, Kumar Vishwanathan G, Dass J, Tyagi S, Mahapatra M, Seth T. Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country. Leuk Lymphoma 62(6):1514-1517, 2021. e-Pub 2021. PMID: 33448885.
- Senapati J, Aggarwal M, Louis L, Mirza SA, Kumar P, Dhawan R, Dass J, Vishwanathan GK, Pandey HC, Coshic P, Tyagi S, Seth T, Mahapatra M. Transfusion practices during the COVID-19 pandemic: An experience from a hematology daycare in India. Transfus Apher Sci 60(2):103025, 2021. e-Pub 2021. PMID: 33353804.
- Senapati J, Devasia AJ, Alex AA, George B. Early T cell precursor lymphoid blast crisis of chronic myeloid leukemia - a novel transformation. Hematol Oncol Stem Cell Ther 8(1):43-6, 2015. e-Pub 2015. PMID: 25497977.
- Senapati J, Devasia AJ, David S, Manipadam MT, Nair S, Jayandharan GR, George B. Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature. Indian J Hematol Blood Transfus 30(Suppl 1):309-13, 2014. e-Pub 2014. PMID: 25332606.
- Senapati J, Devasia AJ, Sudhakar S, Viswabandya A. Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma--a case report and review of literature. Ann Hematol 93(9):1599-602, 2014. e-Pub 2014. PMID: 24362455.
- Senapati J, Devasia AJ, Ganapule A, George L, Viswabandya A. Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature. Mediterr J Hematol Infect Dis 6(1):e2014016, 2014. e-Pub 2014. PMID: 24678393.
Review Articles
- Haddad, FG, Kantarjian, HM, Senapati, J, Jain, N, Short, NJ, Jabbour, EJ. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant. Clinical Lymphoma, Myeloma and Leukemia 25(10):711-719, 2025. e-Pub 2025. PMID: 40683769.
- Haddad, FG, Kantarjian, HM, Short, NJ, Jain, N, Senapati, J, Ravandi-Kashani, F, Jabbour, EJ. Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy. JNCCN Journal of the National Comprehensive Cancer Network 23(8), 2025. e-Pub 2025. PMID: 40659041.
- Senapati, J, Kadia, TM, Daver, N, DiNardo, C, Borthakur, G, Ravandi-Kashani, F, Kantarjian, HM. Therapeutic horizon of acute myeloid leukemia. Cancer 131(7), 2025. e-Pub 2025. PMID: 40105906.
- Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, Jabbour E. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma:1-12, 2025. e-Pub 2025. PMID: 39791458.
- Ray, A, Jain, A, Vijayaran, M, Thomas, S, Senapati, J, Aggarwal, M. MOVING THE NEEDLE IN KMT2A REARRANGED PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Clinical Hematology International 7(2):65-73, 2025. e-Pub 2025. PMID: 40584390.
- Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(6):333-339, 2024. e-Pub 2024. PMID: 38195323.
- Banerjee P, Senapati S. Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases. Stem Cell Rev Rep. e-Pub 2024. PMID: 38758462.
- Short, NJ, Senapati, J, Jabbour, EJ. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Current hematologic malignancy reports 18(6):234-242, 2023. e-Pub 2023. PMID: 37651057.
- Senapati J, Kadia TM, Ravandi F. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica 108(9):2289-2304, 2023. e-Pub 2023. PMID: 37139599.
- Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
- Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 13(1):58, 2023. e-Pub 2023. PMID: 37088793.
- Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37(1):5-17, 2023. e-Pub 2023. PMID: 36309558.
- Senapati J, Sasaki K. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626137.
- Senapati J, Kadia TM. Which FLT3 Inhibitor for Treatment of AML?. Curr Treat Options Oncol 23(3):359-380, 2022. e-Pub 2022. PMID: 35258791.
- Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. e-Pub 2022. PMID: 36383908.
Other Articles
- Senapati, J, Daver, N, Jain, J, Mims, A Concomitant or sequential lower intensity triplet therapy in AML. The Lancet Haematology 13(4):e197-e198, 2026. PMID: 41934991.
- Haque, EU, Jabbour, EJ, Senapati, J, Haddad, FG Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase. Annals of Blood 9, 2024.
Editorials
- Senapati, J, Daver, N. Microclone with megaimpact. Blood 148(5):529-530, 2026. PMID: 42486803.
- Senapati, J, Short, NJ. Advances in Acute Lymphoblastic Leukemia Review Series. Acta haematologica 149(1):5-7, 2026. PMID: 40730141.
- Senapati, J, Jabbour, EJ. Dar-ting at CD38 in T-cell leukemias. Blood 144(21):2162-2164, 2024. PMID: 39570597.
Book Chapters
- Senapati J. Chronic Lymphocytic Leukemia. In: Cancer Consult. 2. Wiley Blackwell, 2023.
Letters to the Editor
- Fang, H, Khoury, J, Tang, Z, Wang, SA, DiNardo, C, Loghavi, S, Wang, WJ, Dimopoulos, YP, Hu, S, Yin, CC, El Hussein, S, Zhang, H, Senapati, J, Chien, KS, Andreeff, M, Medeiros, LJ, Wang, W. p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases. American journal of hematology 101: 2481-2485, 2026.
- Arora, S, Kantarjian, HM, Sasaki, K, Jain, N, Li, Z, Qiao, W, Loghavi, S, Tang, G, Rausch, C, Ravandi-Kashani, F, Haddad, FG, Senapati, J, Montalban Bravo, G, Bazinet, A, Khouri, R, Garris, R, Garcia-Manero, G, Short, NJ, Jabbour, EJ. Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL. American journal of hematology 101: 2038-2043, 2026.
- Goulart, H, Jabbour, EJ, Short, NJ, Jain, N, Issa, GC, Atluri, H, Bataller Torralba, A, Kadia, TM, Daver, N, DiNardo, C, Garris, R, Senapati, J, Ravandi-Kashani, F, Kantarjian, HM. Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens. American journal of hematology 100: 2128-2133, 2025.
- Azevedo, RS, Wang, S, Swanson, DM, Daver, N, Pemmaraju, N, Kadia, TM, Issa, GC, Yilmaz, M, Borthakur, G, Senapati, J, Jen, WY, Short, NJ, Ravandi-Kashani, F, Wang, W, Fang, H, Xu, J, Patel, KP, Tang, G, Medeiros, LJ, DiNardo, C, Loghavi, S. CD123 expression and its correlation with mutation profile in acute myeloid leukaemia. British Journal of Haematology 207: 1648-1652, 2025.
- Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
- Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
- Kontoyiannis, PD, Peddireddy, A, Sasaki, K, Chien, KS, Senapati, J, Montalban Bravo, G, DiNardo, C, Borthakur, G, Kanagal-Shamanna, R, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G, Urrutia, S. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. Leukemia Research 147, 2024.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
Patient Reviews
CV information above last modified September 09, 2026